Showing results (111-120 of 2,336) with videos related to
Sort By:
Pageof 234
Clinical Lung Cancer|February 7, 2026
Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated ReviewAnson Man Lok Yeung, James Chung Hang ChowClinical Lung Cancer|January 28, 2026
Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical TrialTetsuya Takagawa, Kanae Takahashi, Yuji Orimoto, et al.Clinical Lung Cancer|January 16, 2026
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab UseUtsav Joshi, Faustine Ong, Daniel Melzer, et al.Clinical Lung Cancer|March 23, 2025
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)Romain Corre, Chantal Decroisette, Jean-Bernard Auliac, et al.Clinical Lung Cancer|March 23, 2025
Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic ProfilesPrabhat Singh Malik, Neha Pathak, Aparna Sharma, et al.Clinical Lung Cancer|November 6, 2003
Dermatologic side effects associated with gefitinib therapy: clinical experience and managementRoy S Herbst, Patricia M LoRusso, Michele Purdom, et al.Clinical Lung Cancer|December 9, 2003
Second-line chemotherapy for small-cell lung cancer: a reviewC P Schultheis, M A Raheem, M C PerryClinical Lung Cancer|December 9, 2003
Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: an interim reportB Movsas, R S Hudes, J Schol, et al.Clinical Lung Cancer|December 10, 2003
The value of platinum compounds in non-small-cell lung cancerNasser H Hanna, Lawrence H EinhornPageof 234